安罗替尼联合同步适形调强放疗治疗局部晚期NSCLC患者的效果研究  

Study on the Effect of Anrotini Combined with Concurrent Intensity-modulated Radiotherapy in the Treatment of Locally Advanced NSCLC Patients

作　　者：唐冬艳 陈思敏 黄静仪 张慕娟[1] 王人灵 TANG Dongyan;CHEN Simin;HUANG Jingyi;ZHANG Mujuan;WANG Renling(The Second Tumor Region,Kaiping Central Hospital,Jiangmen 529300,Guangdong,China)

机构地区：[1]开平市中心医院肿瘤二区,广东江门529300

出　　处：《中国药物滥用防治杂志》2023年第6期1020-1024,共5页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：2020年度江门市医疗卫生科技计划项目(编号:2020YLJ007)。

摘　　要：目的:探讨安罗替尼联合同步适形调强放疗对局部晚期非小细胞肺癌(NSCLC)患者近期疗效、肿瘤标记物水平及免疫功能的影响。方法:选取2020年3月—2021年12月江门市开平市中心医院就诊的晚期NSCLC患者60例,使用随机数字表法将患者分为观察组和对照组,每组30例。观察组予以安罗替尼联合同步适形调强放疗,对照组予以安慰剂联合同步适形调强放疗。比较两组治疗效果、血清肿瘤标志物水平[血清癌胚抗原(CEA)、细胞角蛋白(CYFRA21-1)及血管内皮生长因子(VEGF)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平)和生活质量。结果:治疗后,观察组客观缓解率为66.67%,高于对照组的40.00%(P<0.05);观察组疾病控制率为96.67%,高于对照组的73.33%(P<0.05);观察组CEA、CYFRA21-1及VEGF水平低于对照组(P<0.05);观察组血清CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组(P<0.05);观察组生活质量核心问卷(QLQ-C30)中功能和总体质量子量表评分高于对照组,QLQ-C30中症状和单项目子量表及肺癌专项量表(QLQ-LC13)评分低于对照组(P<0.05)。结论:安罗替尼联合同步放射治疗可增强对局部晚期NSCLC患者的治疗效果,降低肿瘤标志物表达水平,改善免疫功能及生活质量。Objective:To investigate the effect of anrotini combined with concurrent conformal intensity modulated radiation therapy on the short-term efficacy,tumor marker level and immune function of patients with locally advanced non-small cell lung cancer(NSCLC).Methods:Sixty patients with advanced NSCLC in Kaiping Central Hospital of Jiangmen City from March 2020 to December 2021 were selected and randomly divided into observation group and control group,with 30 cases in each group.The observation group was treated with Anlotinib combined with concurrent intensity modulated radiation therapy,and the control group was treated with placebo combined with concurrent intensity modulated radiation therapy.The therapeutic effect,serum tumor markers[serum carcinoembryonic antigen(CEA),cytokeratin(CYFRA21-1)and vascular endothelial growth factor(VEGF)],immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and quality of life were compared between the two groups.Results:After treatment,the objective remission rate of the observation group was 66.67%,which was higher than 40.00%of the control group(P<0.05).The disease control rate of the observation group was 96.67%,which was higher than 73.33%of the control group(P<0.05).The levels of CEA,CYFRA21-1 and VEGF in the observation group were lower than those in the control group(P<0.05).The levels of serum CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group(P<0.05).The scores of functional and overall quality subscales in the quality of life core questionnaire(QLQ-C30)in the observation group were higher than those in the control group,and the scores of symptoms and single item subscales and lung cancer special scale(QLQ-LC13)in the QLQ-C30 were lower than those in the control group(P<0.05).Conclusion:Anlotinib combined with concurrent radiotherapy can enhance the therapeutic effect of locally advanced NSCLC patients,reduce the expression level of tumor markers,and imp

关 键 词：NSCLC 安罗替尼 同步适形调强放疗 肿瘤标记物 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]